Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort

BACKGROUND: The timely addition of anlotinib to the nab-paclitaxel/gemcitabine regimen may further increase the treatment efficacy for pancreatic adenocarcinoma (PDAC), which has not yet been reported. Therefore, we aimed to compare the efficacy and safety of anlotinib plus nab-paclitaxel/gemcitabin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Hongyang, Huang, Nana, Zhao, Chenchen, Hu, Xueyang, Da, Liangshan, Huang, Wei, Shen, Yuanyuan, Xiong, Fuxing, Zhang, Congjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011259/
https://www.ncbi.nlm.nih.gov/pubmed/35433955
http://dx.doi.org/10.21037/atm-22-544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011259/
https://www.ncbi.nlm.nih.gov/pubmed/35433955
http://dx.doi.org/10.21037/atm-22-544

Ejemplares similares